Abstract With rapidly declining costs, whole genome sequencing is becoming feasible for widespread use. Although cost-effectiveness is driving increased use of the technology, comprehensive recommendations on how to handle ethical dilemmas have yet to reach a consensus. In this article, Sam shares her experience of undergoing whole genome sequencing. Despite the deeply private nature of the test, the results do not solely belong to Sam; her identical twin sister, Arielle, shares virtually the same genome and received results without a formal consent process. This article explores their parallel experiences as a way of highlighting the controversial ethics of a private test with familial implications.
BWho in this room would like to have their whole genome sequenced?^The excitement in the genetics seminar was palpable. BNow you can get sequenced and a clinical interpretation for only $3100,^the medical geneticist continued. With increasing affordability, clinical whole genome sequencing is now accessible to ostensibly healthy individuals (Christensen et al. 2015; Jackson 2015) . For the researchers in the audience, getting the opportunity to discover the secrets hiding within their cells would be as fortuitous as Charlie winning the golden ticket to Willy Wonka's chocolate factory.
Whole genome sequencing can be desired for many reasons including altruism towards scientific research, curiosity, and financial or emotional preparation in the case of suspected disease alleles (Sanderson et al. 2016) . For Sam, a genetics PhD candidate, the idea of interacting with her own genome in the same way she had studied the genomes of research subjects would be a dream come true. Plus, with a strong family history of early onset cancer, she wanted to know if she carried a mutation in a cancer predisposition gene.
While genetic tests always influence biological family members to some extent, one family member in particular would be impacted dramatically by these results. Arielle, her identical twin sister, shares virtually all three billion base pairs that make up their genome.
Arielle and Sam were not novices to the world of genetic testing. In fact, it was a genetic test that revealed their zygosity at age 14. The test was a part of a research study at the annual Twins Days Festival in Twinsburg, Ohio. As the largest gathering of twins in the world, the Twins Days Festival is a goldmine for researchers who study heredity; they flock from around the world, exchanging gift cards and candy for a cheek swab and a completed questionnaire. A few months after participating in one such study, Arielle and Sam received a letter revealing their monozygosity (Morell et al. 2007 ). The results were confirmed by two subsequent tests over the next five years. The discovery changed Sam's life, igniting a passion for epigenetics and clinical genetics that inspired her to pursue a career in genetics research.
The first time Sam told Arielle about her desire to get sequenced was as a campaign, requesting that Arielle split the sequencing costs. After all, Arielle was also a scientist, and Sam believed that both sisters would be interested in learning about their shared genome. Instead, Arielle apprehensively wondered if Sam had fully considered the consequences of the test. What if the results found pathogenic variants that were not medically actionable? She worried about the psychological impact this news may bring to them. As a former researcher at the National Human Genome Research Institute (NHGRI), Arielle was also aware of the risks associated with securing genomic information. Despite coming from a clinical test, would the results be private or used for research purposes? Finally, Arielle felt the test was too novel and would not provide Sam with the information she so greatly desired. She thought Sam should wait until technology improved, such as the optimization of longrange sequencing, to make the most out of this opportunity.
Arielle's trepidation was justified. As a clinical test, Sam's sequencing results were required to go into her medical record. Congress passed the Genetic Information Nondiscrimination Act (GINA) in 2008, but its scope is limited (Genetic Information Nondiscrimination Act of 2008). While GINA prevents genetic discrimination for employment and health insurance, it does not cover life, disability or long-term care insurance . In addition, there are indeed significant limitations to today's predominant genome sequencing technology. In current clinically approved next-generation sequencing methods, repetitive regions of the genome and structural variants such as deletions, duplications, and rearrangements are not detectable (Cordero and Ashley 2012; Green et al. 2013; Kircher and Kelso 2010) .
Although Sam appreciated her sister's concerns about these limitations, she chose to continue her fundraising quest. After obtaining sponsorship, she booked an appointment with her primary care physician, as a physician's signature was required for ordering the test.
Sam's doctor highlighted the risks associated with the test as he conducted a rigorous informed consent discussion. BAre you aware that the test results may reveal information about yourself that you would rather not know, such as predispositions for diseases that might not be curable? Are you aware that you could be subject to genetic discrimination for life insurance or long-term disability insurance? Are you aware that if the security system is breached that the electronic delivery of your results could be accessed by someone else?^Although Sam believed the benefits of the results outweighed the risks, receiving the test was only contingent on her consent. As the physician was not a trained clinical geneticist or genetic counselor, the conversation never exceeded the informed consent form provided by the testing company. Moreover, because this was the physician's first time ordering whole genome sequencing for a patient, he had limited experience in referring patients to genetic counselors. Arielle was neither offered counseling nor asked to sign consent forms, even though most risks applied to her as well. Arielle's skepticism remained, as she felt divorced from the process; by not meeting with the physician, she was never debriefed on possible implications or invited to ask questions that would assuage her concerns.
While scientific societies and ethical boards have proposed informed consent guidelines for whole genome sequencing since its first application to clinical diagnosis in 2009, there is currently no consensus on what constitutes the requirements for informed consent of a genetic test (Jamal et al. 2013; Platt et al. 2014; Roche and Berg 2015) . For example, one study that performed a rigorous examination of these recommendations revealed that only two-thirds discuss Bpossible disadvantages, risks, or complications^as part of the informed consent process, and only a single set of recommendations explicitly included a discussion of relatives as a part of the informed consent conversation (Ayuso et al. 2013; Sijmons et al. 2011) . These policies are insufficient given the prevalence of this controversy; it has been estimated that almost a quarter of genetics health professionals have faced the ethical dilemma of whether to provide a genetic test to one identical twin who wishes to know his or her genetic status when the other twin disapproves (McLean et al. 2013) . While monozygotic twinning occurs spontaneously in approximately 1 in 250 live births, this rate is anticipated to double in the wake of assisted reproductive technologies (Hankins and Saade 2005) . The growing number of identical twins highlights the urgency with which policies must be established to protect this population.
Weeks passed by and Sam started to worry about how she would handle the discovery of a pathogenic variant in her genome. She feared that she would learn something so terrifying that she wouldn't want to bear the responsibility of telling her sister. As her anticipation heightened, she started to feel protective about the privacy of her results. Why did she feel obligated to share her private medical test results with Arielle? Most recommendations regarding returning genomic results to family members prioritize privacy and confidentiality over the desires of relatives (Wolf et al. 2015) . However, the one case where there is currently no consensus is how to handle the discovery of highly pathogenic but medically actionable variants that could have serious implications for closely related family members likely to harbor the same mutation (Godard et al. 2006; Sijmons et al. 2011; Wolf et al. 2015) . Arielle refused to accept Sam's resistance to sharing the results. She felt violated that Sam could withhold information that equally belonged to both of them, despite the original source of the tested blood. After many conversations, the sisters realized they needed to devise a compromise on their own, given that neither of their interests were fully protected by current ethical recommendations. Despite Sam's legal right to submit her sample for whole genome sequencing without Arielle's consent, both sisters agreed that Sam had the responsibility to share her sequencing results with Arielle, as any important findings could inform Arielle's future healthcare decisions.
A few months later, the results finally arrived. After Sam met with her physician to discuss the clinical and pharmacogenomics reports, she prepared to share the results with Arielle. BThe things I'm going to tell you today are only scratching the surface of the information that's here,^Sam explained. BThere are limitations to the test, and there are even more limitations to our ability to analyze the results. We have clinical interpretation for almost 2,000 disease-causing genes out of over 25,000 genes in the human genome. Everything else is up to us to explore, and future scientific research to discover.D espite the wealth of information provided, Sam admitted to Arielle that she was disappointed by the results. She was overwhelmed by the amount of data given and yet frustrated that the majority of it was currently uninterpretable. Arielle comforted her, reminding Sam that while the clinical interpretation was not comprehensive, they could at least feel relief in knowing that no severe clinically significant findings were identified to date.
Whole genome sequencing provided the sisters with more questions than answers. Arielle and Sam don't carry any known cancer predisposition mutations out of the clinically interpreted genes, but would any mutations in the 23,000 genes that were not assessed one day be shown to cause a cancer predisposition? What is hiding in the unexplored depths of their genome? While they face many uncertainties in the aftermath of receiving whole genome sequencing results, one thing is certain. There is a pressing need to educate patients on how their genetic testing will affect family members and to provide resources for vulnerable relatives. Sam and Arielle were fortunate to have devised a compromise that worked for them, but not all identical twins will have these important conversations.
